RGA enters mid-May with a constructive analyst setup that sits in visible contrast to a stock that has barely moved this week — and the gap between where analysts think it should trade and where it actually trades is the most interesting tension right now.
The stock closed Friday at $210.15, up just over 2% for the month but flat on the week (-0.2%). The mean analyst price target of $250.22 implies roughly 19% upside from current levels. That's a meaningful gap for a large-cap reinsurer with a $13.8 billion market cap, and it has held up through a week of active analyst engagement.
The Street's direction has been unmistakably positive this week. JP Morgan raised its target to $270 from $264 on May 7, maintaining Overweight. Barclays followed on May 8, lifting its target to $268 from $256, also keeping an Overweight rating. The only mild exception came from Piper Sandler on May 11, which nudged its target a fraction lower to $261 from $263 while staying at Overweight. The picture that emerges is a group of bellwether firms with virtually identical convictions: the business is performing, but the stock has lagged. UBS remains the lone hold at Neutral, with a $220 target — more in line with where RGA actually trades. Bulls point to improving new-money yields (6.04%), a higher operating ROE target of 13%-15%, and an 8%-10% EPS growth path. Bears flag headwinds in Asia Pacific, higher-than-expected corporate costs, and the drag from international units on near-term earnings. The most recent Q1 print on May 7 sent the stock down 1.9% over the following session and 1.6% over the following five days — a modest negative reaction, not a collapse.
Short positioning offers essentially no drama. SI as a percentage of free float is just 1.43%, and it has fallen 6.5% over the past week to roughly 941,000 shares. Days to cover is under half a day at 0.38. The borrow market is loose by any measure — availability is effectively unconstrained — and cost to borrow, though up 70% over the past week, remains at a near-negligible 0.51% annualised. That week-on-week spike in CTB looks sharp in percentage terms, but in absolute terms it is moving from one trivial level to another slightly less trivial one. There is no squeeze dynamic here, no accumulation of bearish conviction. The short score of 30.7 out of 100 reflects exactly that.
Options positioning, however, has turned more cautious than the short interest data would suggest. The put/call ratio is running at 1.01 — well above its 20-day average of 0.72 — placing it roughly 1.3 standard deviations above the mean. That shift began sharply in early May: before May 7, the PCR was consistently in the 0.49-0.64 range, reflecting a broadly neutral-to-bullish options market. After the earnings print, it jumped above 1.04 and has stayed there. Options traders appear to be adding hedges in the wake of the results, even as equity analysts are lifting targets. That divergence is worth noting — it is not a flashing red signal, but it marks a shift in the risk-appetite tone among derivatives participants.
Institutional ownership is deep and diversified. Vanguard holds 10.6% and BlackRock 9.9%, with FMR (Fidelity) at 8.8% and Harris Associates at 6.5% — a concentrated passive-and-quality-active base that provides relative float stability. Harris added over 915,000 shares in the period ending December 2025, the largest single institutional build in the table. On the valuation side, the trailing P/E is 7.66x, down modestly over the past week as the stock ticked lower, while the P/B ratio is 0.93x. For a reinsurer running toward double-digit ROE targets, sub-1x book is not alarming, but it does reflect the market's scepticism about how quickly that ROE improvement arrives. The dividend score ranks in the 94th percentile, though the most recent dividend data on file dates to 2022 — so that metric is best treated with caution.
The key watch in the coming weeks is whether the gap between the $210 price and the analyst consensus above $250 begins to close, or whether further caution in options positioning signals that investors need more evidence from the Asia Pacific segment before re-rating the stock higher.
See the live data behind this article on ORTEX.
Open RGA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
